AbbVie will present new data from its expanding antibody-drug conjugate (ADC) portfolio at the upcoming European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17–21 in Berlin, Germany.

The data, spanning investigational and approved ADCs such as telisotuzumab adizutecan (Temab-A), ABBV-706, and Emrelis (telisotuzumab vedotin), underscore AbbVie’s continued leadership in developing innovative targeted therapies for patients with advanced and difficult-to-treat solid tumors.

“Despite significant advances in cancer care, patients with advanced solid tumors continue to face limited treatment options and pressing unmet needs,” said Daejin Abidoye, M.D., vice president, therapeutic area head, oncology, solid tumor and hematology, AbbVie. “The data we are sharing at ESMO reinforce our commitment to advancing targeted therapies across a broad range of solid tumors and highlight the potential of our growing ADC platform.”

At ESMO 2025, AbbVie will present three oral presentations on Temab-A, a next-generation, investigational c-Met–directed ADC featuring a novel topoisomerase I inhibitor (Top1i) payload. New Phase 1 data demonstrate the agent’s encouraging clinical activity both as a monotherapy and in combination with other treatments across multiple tumor types.

In colorectal cancer (CRC), Temab-A in combination with bevacizumab (Bev) showed an objective response rate (ORR) of 26.7 per cent among patients who had received three or more prior lines of therapy (NCT05029882), compared with 0 per cent for the standard of care (trifluridine/tipiracil plus Bev). Grade ≥3 treatment-emergent adverse events (TEAEs) occurred in 67 per cent of patients receiving Temab-A plus Bev and 65 per cent in the control arm.

“Temab-A continues to show meaningful clinical activity across a broad range of solid tumors, including in patients with MET amplification and elevated c-Met expression,” said Vivek Subbiah, M.D., Chief, Early-Phase Drug Development, Sarah Cannon Research Institute, and investigator for the Temab-A studies. “These results reinforce Temab-A’s potential as a promising treatment option for multiple solid tumor types and support continued clinical investigation.”